Posters

      Nicotine Pharmacokinetics and Subjective Effects Following Use of a Novel Nicotine-Containing Powder Product

      Bosilkovska, M.; Fredersdorf, S.; Almodovar, J.; Lama, N.; Taranu, B.; Pierri, E.; Radicioni, M.; Ancerewicz, J. Ancerewicz.; Haziza, C.; Lüdicke, F.

      Conference date
      Feb 22, 2019
      Conference name
      Society for Research on Nicotine and Tobacco (SRNT) 2019
      Link to more information
      Topic
      Summary

      Background: Novel nicotine delivery systems, delivering nicotine without smoke, are complementary to tobacco harm reduction strategy. We present the first data from the clinical assessment of a novel nicotine-containing product, similar in appearance to a cigarette, that generates an inhalable aerosol from nicotine powder when air is drawn through it without the help of electronics. Methods: This was an open-label, randomized, crossover study to evaluate the nicotine pharmacokinetic (PK) profiles of four product variants, differing in nicotine content (1 or 2 mg), nicotine-powder particle size, and presence/absence of mentholated flavor, following a fixed puffing regimen and a one-hour ad libitum use period. A compartmental PK analysis approach was used to perform nicotine baseline correction. Safety and product satisfaction were assessed to provide further insights on product acceptance and product use. Eighteen healthy adult smokers were randomized in this study conducted in Switzerland and registered at www.clinicaltrials.gov (NCT03369340). Results: The mean of maximal nicotine concentrations (Cmax) ranged between 1.1 and 3.1 ng/mL for the different product variants during fixed regimen and were reached after 15–22.5 minutes. During each ad libitum session, subjects used between one and four products to reach maximal nicotine concentrations (Cpeak) between 2.6 and 5.4 ng/mL. Lowest extent of nicotine exposure was observed for the 1 mg variant, while the presence/absence of flavor and nicotine powder particle size did not influence the PK parameters for both regimens. Product satisfaction, assessed using an adapted version of the modified cigarette evaluation questionnaire, was similar across variants, with slightly lower scores for the unflavored variant, and was also similar to previously reported scores for cigarettes. Product variants were well tolerated, as indicated by the adverse events collection, safety monitoring, and cough assessment. Conclusions: This novel nicotine-containing product shows potential as an alternative to cigarettes for smokers in terms of product satisfaction and simplicity of use without the involvement of electronics.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.